|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:activeIngredient
|
gamma-hydroxybutyric acid
|
|
gptkbp:approvalYear
|
2002 (US)
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N07XX04
|
|
gptkbp:brand
|
gptkb:Xyrem
gptkb:Xywav
|
|
gptkbp:broadcastOn
|
gptkb:Schedule_III_(US)
|
|
gptkbp:CASNumber
|
502-85-2
|
|
gptkbp:chemicalClass
|
oxybates
|
|
gptkbp:contraindication
|
succinic semialdehyde dehydrogenase deficiency
concurrent use with alcohol
|
|
gptkbp:discoveredBy
|
gptkb:Alexander_Zaytsev
|
|
gptkbp:eliminationHalfLife
|
0.5–1 hour
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
oral solution
|
|
gptkbp:hasMolecularFormula
|
C4H7NaO3
|
|
gptkbp:legalStatus
|
gptkb:controlled_substance
|
|
gptkbp:mechanismOfAction
|
GHB receptor agonist
GABAB receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
126.09 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
enuresis
|
|
gptkbp:usedFor
|
narcolepsy
excessive daytime sleepiness
cataplexy
|
|
gptkbp:bfsParent
|
gptkb:Idiopathic_hypersomnia
gptkb:Narcolepsy_type_1
gptkb:Xyrem
gptkb:Xywav
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sodium oxybate
|